Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Opinion & Analysis (NDAQ:BLUE)

    Coverage Initiated on Cancer Vaccine Firm

    Streetwise Reports March 11, 2019

    Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

    Streetwise Reports April 25, 2018

    Partnerships propel Stellar Biotechnologies' vaccine technology

    The Life Sciences Report June 22, 2016

    CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

    Gail Dutton September 10, 2015

    Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

    George S. Mack September 3, 2015

    Zacks' Jason Napodano is not focused on a biotech bubble

    George S. Mack July 9, 2015